|
⚲
|
| Elite Pharmaceuticals Inc /DE/ | |
|---|---|
| Firm | |
| Fund # | |
| CIK # | 0001053369 |
| Sale | 2009-06-03 ($3.8 M Offered, $1.0 M Sold) |
| Fund | |
| Phone | 2017502646 |
| Address | 165 Ludlow Avenue Northvale, 07647 |
| Source | [EDGAR] |
| Fund AUM and Sold ($k) |
|---|
| Fund Details | |
|---|---|
| Director | |
| Custodian | |
| Auditor | |
| Marketer | |
| Broker | |
| Jurisdiction |
| Directors | 2011 - 2026 |
|---|---|
| Chris Dick | |
| Jerry Treppel | |
| Robert Levenson | |
| Mark Gittelman | |
| Melvin van Woert | |
| Barry Dash |
| Comparable Firms | State | AUM ($B) |
|---|---|---|
|
MBX Capital II-A, LP
✚
|
0.0 | |
|
McBeath Kathryn
✚
|
0.0 | |
|
McCabe Peter David
✚
|
0.0 | |
|
McCafferty Terence M.
✚
|
0.0 | |
|
McCann Corey
✚
|
0.0 | |
|
McCormick Michael W
✚
|
0.0 | |
|
McCourt Martin
✚
|
0.0 | |
|
McCoy Sarah Gaines
✚
|
0.0 | |
|
McCree Douglas I.
✚
|
0.0 | |
|
MBV R2G REIT LLC
✚
|
0.0 |